Attractive Targeted Sugars: Exploring the Sweet Side of Drug Development

Alexander Wang^*
*Correspondence: Alexander Wang, Department of Ophthalmology, Jagiellonian University, Kopernika Str. 38, 31-501 Krakow, Poland, Email:

Abstract

Vivax malaria, caused by the Plasmodium vivax parasite, presents unique challenges due to its ability to form dormant liver stages, leading to recurrent infections weeks or even months after the initial mosquito bite. This article reviews recent advancements in vivax malaria treatment strategies, focusing on innovations targeting both the acute blood-stage infection and the dormant liver stages. Artemisinin-based Combination Therapies (ACTs) remain effective against the blood-stage infection, although emerging drug resistance poses a threat. Primaquine is essential for eliminating hypnozoites, but its use is complicated by the risk of hemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency. Recent innovations in G6PD deficiency testing have improved safety, while alternative therapies are being explored. Advancements in treatment delivery, such as point-of-care diagnostics and mobile health technologies, enhance access, particularly in remote settings. Challenges persist, including limited healthcare access, drug resistance, and the complex biology of P. vivax. Continued innovation and collaboration are essential to overcome these challenges and improve treatment outcomes, ultimately advancing towards malaria elimination.

Keywords

Vivax malaria • Hemolysis • Mosquito bite

Introduction

Vivax malaria, caused by the Plasmodium vivax parasite, poses a significant global health burden, particularly in regions with tropical and subtropical climates. Unlike its more deadly counterpart, Plasmodium falciparum, vivax malaria presents unique challenges due to its ability to form dormant liver stages called hypnozoites, leading to recurrent infections weeks or even months after the initial mosquito bite. Addressing this relapsing nature of the disease requires innovative treatment strategies that target both the acute blood-stage infection and the dormant liver stages. In recent years, there have been notable advancements in vivax malaria treatment, accompanied by inherent challenges that must be addressed to improve patient outcomes and accelerate progress towards malaria elimination [1].

Literature Review

The cornerstone of vivax malaria treatment is the use of antimalarial drugs to eliminate the parasite from the bloodstream. Artemisinin-based combination therapies (ACTs), which combine artemisinin derivatives with other antimalarial drugs, are highly effective against the blood-stage infection of P. vivax. These therapies rapidly reduce parasite levels, alleviate symptoms, and prevent complications. However, the emergence of drug resistance, particularly to the partner drugs in ACTs, poses a significant threat to their efficacy. Continuous surveillance and monitoring of drug resistance are essential to ensure the continued effectiveness of ACTs in vivax malaria treatment. A unique challenge in vivax malaria treatment is the presence of dormant liver stages, which can cause relapses of the disease long after the initial infection. Primaquine, an 8-aminoquinoline drug, is the only licensed therapy capable of eliminating hypnozoites and preventing relapses. However, primaquine administration is complicated by the risk of hemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency, a common genetic disorder. Recent innovations in G6PD deficiency testing have improved the safety and accessibility of primaquine therapy, enabling healthcare providers to identify at-risk individuals and tailor treatment accordingly. Additionally, novel drug regimens and alternative therapies are being investigated to overcome the limitations of primaquine and provide safer and more effective options for radical cure [2,3].

Discussion

Advancements in treatment delivery mechanisms are also enhancing access to vivax malaria treatment, particularly in remote and resource-limited settings. Point-of-care diagnostic tools enable rapid and accurate diagnosis of vivax malaria, allowing for timely initiation of treatment. Mobile health technologies and community-based approaches facilitate decentralized delivery of antimalarial drugs and support patient adherence to treatment regimens. Furthermore, partnerships between public health agencies, non-governmental organizations, and the private sector are expanding access to essential medicines and strengthening healthcare systems, thereby improving the delivery of vivax malaria treatment to those in need. Despite these advancements, several challenges persist in the treatment of vivax malaria. Limited access to healthcare services, inadequate infrastructure, and socioeconomic factors hinder the delivery of effective treatment to vulnerable populations. Drug resistance, particularly to primaquine, remains a concern, necessitating continued research into alternative therapies and combination regimens. Moreover, the complex biology of the P. vivax parasite, including its ability to evade host immune responses and persist in the liver, presents ongoing challenges for drug discovery and development [4-6].

Conclusion

In conclusion, advancing treatment strategies for vivax malaria requires a multi-faceted approach that addresses both the acute blood-stage infection and the dormant liver stages of the disease. Innovations in drug development, diagnostic testing, and treatment delivery are improving the efficacy, safety, and accessibility of vivax malaria treatment. However, concerted efforts are needed to overcome remaining challenges and ensure equitable access to quality care for all individuals affected by vivax malaria. By harnessing the power of innovation and collaboration, we can accelerate progress towards the goal of malaria elimination and improve health outcomes for millions of people worldwide.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Adams, John H and Ivo Mueller. "The biology of Plasmodium vivax." Harb Perspect Med 7 (2017): a025585.

Google Scholar, Crossref, Indexed at

2. Battle, Katherine E., Tim CD Lucas, Michele Nguyen and Rosalind E. Howes, et al. "Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: A spatial and temporal modelling study." The Lancet 394 (2019): 332-343.

Google Scholar, Crossref, Indexed at

3. Price, Ric N., Lorenz Von Seidlein, Neena Valecha and Francois Nosten, Jet al. "Global extent of chloroquine-resistant Plasmodium vivax: A systematic review and meta-analysis." The Lancet infectious diseases 14 (2014): 982-991.

Google Scholar, Crossref, Indexed at

4. Bruce, Marian C., Mary R. Galinski, John W. Barnwell and Georges Snounou, et al. "Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: Global and local diversity." Am J Trop Med Hyg 61 (1999): 518-525.

Google Scholar, Crossref, Indexed at

5. Motshoge, Thato, Grace K. Ababio, Larysa Aleksenko and John Read, et al. "Molecular evidence of high rates of asymptomatic P. vivax infection and very low P. falciparum malaria in Botswana." BMC Infect Dis 16 (2016): 1-8.

Google Scholar, Crossref, Indexed at

6. Spanakos, Gregory, Michael Alifrangis, Mette L. Schousboe and Eleni Patsoula, et al. "Genotyping Plasmodium vivax isolates from the 2011 outbreak in Greece." Malar J 12 (2013): 1-8.

Google Scholar, Crossref, Indexed at